Literature DB >> 15828839

Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase.

Pratap Singh1, Anastasiah M Mhaka, Soren B Christensen, Jeffrey J Gray, Samuel R Denmeade, John T Isaacs.   

Abstract

Noncompetitive inhibitors of sarco- and endoplasmic reticulum calcium-ATPase (SERCA) have important therapeutic value in the treatment of cancer, due to their ability to induce apoptosis in cancer cells in a proliferation-independent manner. Thapsigargin (TG) and its analogues are one such class of inhibitors that bind to a hydrophobic pocket located in the transmembrane region of SERCA near the biomembrane surface and interfere with calcium transport. The binding free energies of thapsigargin-based inhibitors of SERCA were computed using a novel linear interaction energy (LIE) method with a surface generalized Born (SGB) continuum solvation model. A training set of 20 TG analogues was used to build a binding affinity model for estimating the free energy of binding for 18 new inhibitors with a root-mean-square (rms) error of 1.36 kcal/mol with respect to experimental data. For 15 out of the 18 inhibitors in the test set, the rms error was 1.02 kcal/mol, which is on the order of the accuracy level achieved by highly rigorous free energy of perturbation (FEP) or thermodynamic integration (TI) methods. On the basis of the analysis of the binding cavity at the interface of the membrane surface and the cytoplasmic region, we propose that side chains of TG derivatives at the O-8 position orient toward the cytoplasmic region through a hydrophobic channel. On the basis of this insight, four analogues of varying side chain length at the O-8 position with a charged moiety at the end were designed, tested with LIE methodology, and then validated experimentally for their SERCA inhibition activity. Low levels of rms error for the majority of inhibitors establish the structure-based LIE method as an efficient tool for generating more potent and specific inhibitors of SERCA by testing rationally designed lead compounds based on thapsigargin derivatization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15828839     DOI: 10.1021/jm049319a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.

Authors:  Samuel R Denmeade; Annastasiah M Mhaka; D Marc Rosen; W Nathaniel Brennen; Susan Dalrymple; Ingrid Dach; Claus Olesen; Bora Gurel; Angelo M Demarzo; George Wilding; Michael A Carducci; Craig A Dionne; Jesper V Møller; Poul Nissen; S Brøgger Christensen; John T Isaacs
Journal:  Sci Transl Med       Date:  2012-06-27       Impact factor: 17.956

2.  Mathematical investigation of IP3-dependent calcium dynamics in astrocytes.

Authors:  Gregory Handy; Marsa Taheri; John A White; Alla Borisyuk
Journal:  J Comput Neurosci       Date:  2017-03-28       Impact factor: 1.621

3.  Comparison of current docking tools for the simulation of inhibitor binding by the transmembrane domain of the sarco/endoplasmic reticulum calcium ATPase.

Authors:  Michael Lape; Christopher Elam; Stefan Paula
Journal:  Biophys Chem       Date:  2010-02-04       Impact factor: 2.352

4.  Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.

Authors:  W Nathaniel Brennen; D Marc Rosen; Alcides Chaux; George J Netto; John T Isaacs; Samuel R Denmeade
Journal:  Prostate       Date:  2014-07-22       Impact factor: 4.104

5.  Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates.

Authors:  Marco Mor; Alessio Lodola; Silvia Rivara; Federica Vacondio; Andrea Duranti; Andrea Tontini; Silvano Sanchini; Giovanni Piersanti; Jason R Clapper; Alvin R King; Giorgio Tarzia; Daniele Piomelli
Journal:  J Med Chem       Date:  2008-05-29       Impact factor: 7.446

6.  Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.

Authors:  Donald J Vander Griend; Lizamma Antony; Susan L Dalrymple; Yi Xu; S Brogger Christensen; Samuel R Denmeade; John T Isaacs
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

7.  A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma.

Authors:  Devalingam Mahalingam; Julio Peguero; Putao Cen; Sukeshi P Arora; John Sarantopoulos; Julie Rowe; Victoria Allgood; Benjamin Tubb; Luis Campos
Journal:  Cancers (Basel)       Date:  2019-06-17       Impact factor: 6.639

8.  Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.

Authors:  D Mahalingam; G Wilding; S Denmeade; J Sarantopoulas; D Cosgrove; J Cetnar; N Azad; J Bruce; M Kurman; V E Allgood; M Carducci
Journal:  Br J Cancer       Date:  2016-04-26       Impact factor: 7.640

Review 9.  Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics.

Authors:  John T Isaacs; William Nathaniel Brennen; Søren Brøgger Christensen; Samuel R Denmeade
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.